ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
3 hedge funds and large institutions have $170K invested in ELITE PHARMACEUTICAL in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
358% more capital invested
Capital invested by funds: $37.2K → $170K (+$133K)
50% more funds holding
Funds holding: 2 → 3 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$30.7K |
| 2 |
GA
Geneva Advisors
Chicago,
Illinois
|
+$12.5K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GA
1
Geneva Advisors
Chicago,
Illinois
| $115K | +$12.5K | +30,540 | +12% |
|
|
2
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| $30.7K | +$30.7K | +75,000 | New |
|
|
JAFL
3
Jay A. Fishman Ltd
Troy,
Michigan
| $24.6K | – | – | – |
|
ELI Hedge Fund Activity: Q1 2014 in Review
3 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2014, worth a combined $170K — up 358% from $37.2K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Janney Montgomery Scott, opening a new position worth an estimated $30.7K.
- 3 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q1 2014, up from 2 in Q4 2013.
- Funds reported $170K of ELITE PHARMACEUTICAL stock for Q1 2014, up 358% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q1 2014 and 0 closed out, a net change of +1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q1 2014 was Janney Montgomery Scott, an estimated $30.7K added.
Based on aggregated 13F filings for Q1 2014.